Objectives: rIX-FP was developed to extend the half-life of FIX, improving hemophilia B treatment by allowing less frequent dosing than the standard FIX products. Four trials in the PROLONG-9FP clinical program were completed in previously treated adult and pediatric patients with hemophilia B (FIX ≤ 2%). A population pharmacokinetics (PPK) model was developed to characterize rIX-FP pharmacokinetics (PK), to describe and identify demographic and clinical covariates of rIX-FP PK variability and to simulate FIX activity-time profiles for various dosing regimens.
